Epi-drugs and epi-mirs: Moving beyond current cancer therapies

Salarinia, R. and Sahebkar, A. and Peyvandi, M. and Mirzaei, H.R. and Jaafari, M.R. and Riahi, M.M. and Ebrahimnejad, H. and Nahand, J.S. and Hadjati, J. and Asrami, M.O. and Fadaei, S. and Salehi, R. and Mirzaei, H. (2016) Epi-drugs and epi-mirs: Moving beyond current cancer therapies. Current Cancer Drug Targets, 16 (9). pp. 773-788.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs miRNAs are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents. © 2016 Bentham Science Publishers.

Item Type: Article
Additional Information: cited By 0
Subjects: Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Clinical Sciences > Department of Internal Medicine
Depositing User: editor . 2
Date Deposited: 03 Mar 2017 17:19
Last Modified: 03 Mar 2017 17:19
URI: http://eprints.kaums.ac.ir/id/eprint/58

Actions (login required)

View Item View Item